1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Golidocitinib Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 150 mg
  • 1.3.3 100 mg
• 1.4 Market Analysis by Application
  • 1.4.1 Overview: Global Golidocitinib Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.4.2 Relapsed Or Refractory Peripheral T-Cell Lymphoma
  • 1.4.3 Other T-Cell Lymphoma Subtypes
  • 1.4.4 Hematologic Malignancies
  • 1.4.5 Others
• 1.5 Global Golidocitinib Market Size & Forecast
  • 1.5.1 Global Golidocitinib Consumption Value (2021 & 2025 & 2032)
  • 1.5.2 Global Golidocitinib Sales Quantity (2021-2032)
  • 1.5.3 Global Golidocitinib Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 Dizhe (Jiangsu) Pharmaceutical
  • 2.1.1 Dizhe (Jiangsu) Pharmaceutical Details
  • 2.1.2 Dizhe (Jiangsu) Pharmaceutical Major Business
  • 2.1.3 Dizhe (Jiangsu) Pharmaceutical Golidocitinib Product and Services
  • 2.1.4 Dizhe (Jiangsu) Pharmaceutical Golidocitinib Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Dizhe (Jiangsu) Pharmaceutical Recent Developments/Updates

3 Competitive Environment: Golidocitinib by Manufacturer

• 3.1 Global Golidocitinib Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Golidocitinib Revenue by Manufacturer (2021-2026)
• 3.3 Global Golidocitinib Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Golidocitinib by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Golidocitinib Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Golidocitinib Manufacturer Market Share in 2025
• 3.5 Golidocitinib Market: Overall Company Footprint Analysis
  • 3.5.1 Golidocitinib Market: Region Footprint
  • 3.5.2 Golidocitinib Market: Company Product Type Footprint
  • 3.5.3 Golidocitinib Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Golidocitinib Market Size by Region
  • 4.1.1 Global Golidocitinib Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Golidocitinib Consumption Value by Region (2021-2032)
  • 4.1.3 Global Golidocitinib Average Price by Region (2021-2032)
• 4.2 North America Golidocitinib Consumption Value (2021-2032)
• 4.3 Europe Golidocitinib Consumption Value (2021-2032)
• 4.4 Asia-Pacific Golidocitinib Consumption Value (2021-2032)
• 4.5 South America Golidocitinib Consumption Value (2021-2032)
• 4.6 Middle East & Africa Golidocitinib Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Golidocitinib Sales Quantity by Type (2021-2032)
• 5.2 Global Golidocitinib Consumption Value by Type (2021-2032)
• 5.3 Global Golidocitinib Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Golidocitinib Sales Quantity by Application (2021-2032)
• 6.2 Global Golidocitinib Consumption Value by Application (2021-2032)
• 6.3 Global Golidocitinib Average Price by Application (2021-2032)

7 North America

• 7.1 North America Golidocitinib Sales Quantity by Type (2021-2032)
• 7.2 North America Golidocitinib Sales Quantity by Application (2021-2032)
• 7.3 North America Golidocitinib Market Size by Country
  • 7.3.1 North America Golidocitinib Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Golidocitinib Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Golidocitinib Sales Quantity by Type (2021-2032)
• 8.2 Europe Golidocitinib Sales Quantity by Application (2021-2032)
• 8.3 Europe Golidocitinib Market Size by Country
  • 8.3.1 Europe Golidocitinib Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Golidocitinib Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Golidocitinib Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Golidocitinib Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Golidocitinib Market Size by Region
  • 9.3.1 Asia-Pacific Golidocitinib Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Golidocitinib Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Golidocitinib Sales Quantity by Type (2021-2032)
• 10.2 South America Golidocitinib Sales Quantity by Application (2021-2032)
• 10.3 South America Golidocitinib Market Size by Country
  • 10.3.1 South America Golidocitinib Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Golidocitinib Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Golidocitinib Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Golidocitinib Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Golidocitinib Market Size by Country
  • 11.3.1 Middle East & Africa Golidocitinib Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Golidocitinib Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Golidocitinib Market Drivers
• 12.2 Golidocitinib Market Restraints
• 12.3 Golidocitinib Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Golidocitinib and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Golidocitinib
• 13.3 Golidocitinib Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Golidocitinib Typical Distributors
• 14.3 Golidocitinib Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Golidocitinib market size was valued at US$ 233 million in 2025 and is forecast to a readjusted size of US$ 968 million by 2032 with a CAGR of 16.3% during review period.
Golidocitinib is a highly selective, orally bioavailable small-molecule JAK1 inhibitor, mainly used for the treatment of hematologic malignancies such as relapsed or refractory peripheral T-cell lymphoma. The drug specifically inhibits the JAK-STAT signaling pathway, blocking abnormal cell proliferation and inflammatory signal transduction, thereby suppressing tumor cell growth and delaying disease progression. As a new generation of targeted antineoplastic agents, golidocitinib features high target selectivity, low off-target effects, and controllable clinical safety. It provides a new therapeutic option for patients with relapsed and refractory lymphoma and represents one of the important innovative targeted drugs in the field of lymphoma.In 2025, global Golidocitinib production reached approximately 110,000–120,000 bottles.
As a globally first-in-class highly selective JAK1 inhibitor, golidocitinib has precisely filled the long-standing clinical gap in the treatment of relapsed and refractory peripheral T-cell lymphoma since its launch. With its unique mechanism of action and significant survival benefits, it has rapidly established a core position in the targeted market. Relying on its globally exclusive target, breakthrough therapeutic efficacy, and highest-level recommendations from authoritative clinical guidelines, the drug has built strong market competitiveness and technical barriers. Following its inclusion in medical insurance, its accessibility has been greatly improved, market penetration and patient coverage continue to expand, and the commercialization process has accelerated significantly. In terms of competitive landscape, it enjoys obvious first-mover advantages, while similar competitors remain in late-stage clinical development, making it difficult to challenge its dominant position in the short term. Meanwhile, with the active expansion of multiple indications such as first-line treatment, combination therapy, and other T-cell lymphoma subtypes, golidocitinib is extending from second-line salvage therapy to full-course disease management, continuously unlocking its market potential and product life cycle. In the future, it is expected to further consolidate its benchmark value in the global targeted therapy for hematologic malignancies through its differentiated advantages and international layout.
This report is a detailed and comprehensive analysis for global Golidocitinib market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Golidocitinib market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Golidocitinib market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Golidocitinib market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Golidocitinib market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Golidocitinib
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Golidocitinib market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Dizhe (Jiangsu) Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Golidocitinib market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
150 mg
100 mg
Market segment by Application
Relapsed Or Refractory Peripheral T-Cell Lymphoma
Other T-Cell Lymphoma Subtypes
Hematologic Malignancies
Others
Major players covered
Dizhe (Jiangsu) Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Golidocitinib product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Golidocitinib, with price, sales quantity, revenue, and global market share of Golidocitinib from 2021 to 2026.
Chapter 3, the Golidocitinib competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Golidocitinib breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Golidocitinib market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Golidocitinib.
Chapter 14 and 15, to describe Golidocitinib sales channel, distributors, customers, research findings and conclusion.